OnCo
targetsTarget

CD7

A T-cell surface marker kept on most T-cell leukaemias; CAR-T cells against it must be engineered not to kill each other, and they have produced remissions in T-ALL where nothing else worked.

CD7 is expressed on ~95% of T-ALL and T-lymphoblastic lymphoma, many NK/T lymphomas and ~30% of AML. CD7 CAR-T requires fratricide prevention (CD7 knockout, protein expression blockers or naturally selected CD7-negative T cells) and causes T-cell aplasia, so it is used as a bridge to allogeneic transplant. Trials in China (Peking University, Hebei Yanda) reported 90%+ complete remission in relapsed T-ALL (NEJM 2022, universal donor-derived CAR-T), and WU-CART-007 (allogeneic, US) received breakthrough status. Also a target for the ADC and for imaging in T-cell lymphoma.

CD7: what it is and how drugs act on it · animated generic schematic, not to scale
  • Target · the protein and the cell it sits on
  • Drug · antibody, small molecule, cell or radioligand
  • Effect · signal, damage or kill

In plain words · A T-cell surface marker kept on most T-cell leukaemias; CAR-T cells against it must be engineered not to kill each other, and they have produced remissions in T-ALL where nothing else worked.

  1. 1 · What it is

    A T-cell surface marker kept on most T-cell leukaemias; CAR-T cells against it must be engineered not to kill each other, and they have produced remissions in T-ALL where nothing else worked.

  2. 2 · What goes wrong in cancer

    Ig-superfamily transmembrane glycoprotein on thymocytes, mature T and NK cells; ligand is SECTM1/K12; co-stimulatory role in early T-cell development.

  3. 3 · How drugs use it

    No product in this corpus aims at CD7 yet. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.

Biology

Ig-superfamily transmembrane glycoprotein on thymocytes, mature T and NK cells; ligand is SECTM1/K12; co-stimulatory role in early T-cell development.

Where it is found
  • T-ALL / T-LBL (~95%)
  • Extranodal NK/T-cell lymphoma, some PTCL
  • AML (~30%, poor prognosis)
Class
surface antigen · CD7

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this target: (TITLE:"CD7" OR ABSTRACT:"CD7") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD7, not a curated reading list.

Connected

6top